Alexander M. Kaizer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander M. Kaizer has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Justin R. Ryder
Department of Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA
6 shared publications - Rena Yadlapati
Department of Gastroenterology and Hepatology University of California San Diego San Diego California USA
5 shared publications - Brian P. Hobbs
Dell Medical School The University of Texas at Austin Austin Texas USA
4 shared publications Kyle D. Rudser
Center for Pediatric Obesity Medicine University of Minnesota Medical School Minneapolis Minnesota USA
4 shared publicationsJessica Wild
Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
3 shared publications- Joseph Stephen Koopmeiners
Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota , Minneapolis, MN 55414
3 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-22
Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
- 27 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-22
Open AccessMethodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty
- Open Access
- 12 March 2026
- Published by American Speech Language Hearing Association in Journal of Speech, Language, and Hearing Research
- Vol. 69 (3) , 1230-1248
Is There a Relationship Between Infant and Toddler Speech Discrimination Abilities and Mean Length of Utterance at 33 Months?
Purpose: The purpose of this study was to examine the relationship among speech discrimination at 9 months of age, word recognition at 30 months of age, and mean length of utterance in morphemes (MLUm) at 33 months of age among children who are hard of hearing (CHH) and children with normal hearing (CNH). This study also explored early sociodemographic and audiological variables that may influence communication outcomes in CHH and CNH. Method: Participants included 18 CNH and 32 CHH with early and well-fit hearing aids (HAs). Measures included speech discrimination in response to vowel and consonant stimuli at 9 months, word recognition at 30 months, and a spontaneous language sample at 33 months. Results: Group-level differences were not observed in speech discrimination or word recognition but emerged for language outcomes. Specifically for language outcomes, CHH had shorter MLUms and produced fewer mental state verbs than CNH. Vowel discrimination and word recognition were related to each other, and word recognition was related to MLUm. Consonant discrimination did not relate to any other variables. Higher MLUm was related to maternal level of education, hearing status, and daily device use. Additionally, daily device use at both 9 and 30 months correlated with word recognition at 30 months. Conclusions: Early auditory measures (speech discrimination and daily device use) relate to later speech recognition and MLUm in young children wearing well-fit HAs. Clinicians should consider these early metrics, as well as spontaneous language samples to capture real-world conversational skills, to identify young CHH at risk for poorer language outcomes. Supplemental Material: https://doi.org/10.23641/asha.31212223
- 12 March 2026
- Published by American Speech Language Hearing Association in Journal of Speech, Language, and Hearing Research
- Vol. 69 (3) , 1230-1248
Open AccessIs There a Relationship Between Infant and Toddler Speech Discrimination Abilities and Mean Length of Utterance at 33 Months?
Purpose: The purpose of this study was to examine the relationship among speech discrimination at 9 months of age, word recognition at 30 months of age, and mean length of utterance in morphemes (MLUm) at 33 months of age among children who are hard of hearing (CHH) and children with normal hearing (CNH). This study also explored early sociodemographic and audiological variables that may influence communication outcomes in CHH and CNH. Method: Participants included 18 CNH and 32 CHH with early and well-fit hearing aids (HAs). Measures included speech discrimination in response to vowel and consonant stimuli at 9 months, word recognition at 30 months, and a spontaneous language sample at 33 months. Results: Group-level differences were not observed in speech discrimination or word recognition but emerged for language outcomes. Specifically for language outcomes, CHH had shorter MLUms and produced fewer mental state verbs than CNH. Vowel discrimination and word recognition were related to each other, and word recognition was related to MLUm. Consonant discrimination did not relate to any other variables. Higher MLUm was related to maternal level of education, hearing status, and daily device use. Additionally, daily device use at both 9 and 30 months correlated with word recognition at 30 months. Conclusions: Early auditory measures (speech discrimination and daily device use) relate to later speech recognition and MLUm in young children wearing well-fit HAs. Clinicians should consider these early metrics, as well as spontaneous language samples to capture real-world conversational skills, to identify young CHH at risk for poorer language outcomes. Supplemental Material: https://doi.org/10.23641/asha.31212223
- 4 March 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (5) , 1702-1703
Paediatric difficult intubations and the impact of timing of weekend versus weekday cases. Response to Br J Anaesth 2026; 136: 365-6
- 4 March 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (5) , 1702-1703
Paediatric difficult intubations and the impact of timing of weekend versus weekday cases. Response to Br J Anaesth 2026; 136: 365-6
- Open Access
- 19 August 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (5) , 1511-1517
Paediatric difficult intubations and the impact of timing of weekend versus weekday cases: an analysis of the Pediatric Difficult Intubation registry
- 19 August 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 135 (5) , 1511-1517
Open AccessPaediatric difficult intubations and the impact of timing of weekend versus weekday cases: an analysis of the Pediatric Difficult Intubation registry
- Open Access
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500507
Master Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation
PURPOSE: Master protocols represent transformations, enabling multiple therapies or diseases under a single protocol. These designs streamline therapeutic development by reducing redundancies. Suited for evolving fields such as oncology and global emergencies such as the COVID-19 pandemic, master protocols have been exemplified by studies such as RECOVERY, Solidarity, and I-SPY 2, which accelerated effective treatment identification (with I-SPY 2 focused on molecular subtypes). Recent oncology examples, such as MORPHEUS, evaluate immunotherapy combinations with shared controls. Despite advantages, their application in early-phase oncology remains underutilized amid growing regulatory emphasis on randomization for robust evidence. METHODS: US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) initiatives, such as Project Optimus and Project FrontRunner, emphasize randomization in early-phase oncology trials. However, these initiatives pose challenges, including larger sample sizes, patient and physician reluctance to randomization, and high failure rates from poor accrual. To address these, this article adapts master protocol designs to consolidate early-phase trials for novel therapeutics sharing a common backbone therapy, integrating hybrid controls from published standard-of-care data to minimize randomization to the control arm. RESULTS: By consolidating trials under a shared standard-of-care control arm, the proposed master protocol design reduces total sample size by as much as 55% when compared with independent trials (with control arm sizes 2.4-2.9 times lower), lowers costs and duration, and enhances enrollment through reduced randomization to controls. Incorporating hybrid controls from prior studies and sharing information among arms with common background standard-of-care further improve efficiency, increasing power (reaching 90% overall) while controlling type I error rates acceptable levels. CONCLUSION: Master protocol designs with hybrid controls and Bayesian information sharing enable the efficient integration of randomization into early-phase oncology trials, enhancing efficiency, cost-effectiveness, and patient-centricity while aligning with FDA OCE initiatives.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500507
Open AccessMaster Protocol Design With Hybrid Control for Efficient Early-Phase Trial Consolidation
PURPOSE: Master protocols represent transformations, enabling multiple therapies or diseases under a single protocol. These designs streamline therapeutic development by reducing redundancies. Suited for evolving fields such as oncology and global emergencies such as the COVID-19 pandemic, master protocols have been exemplified by studies such as RECOVERY, Solidarity, and I-SPY 2, which accelerated effective treatment identification (with I-SPY 2 focused on molecular subtypes). Recent oncology examples, such as MORPHEUS, evaluate immunotherapy combinations with shared controls. Despite advantages, their application in early-phase oncology remains underutilized amid growing regulatory emphasis on randomization for robust evidence. METHODS: US Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) initiatives, such as Project Optimus and Project FrontRunner, emphasize randomization in early-phase oncology trials. However, these initiatives pose challenges, including larger sample sizes, patient and physician reluctance to randomization, and high failure rates from poor accrual. To address these, this article adapts master protocol designs to consolidate early-phase trials for novel therapeutics sharing a common backbone therapy, integrating hybrid controls from published standard-of-care data to minimize randomization to the control arm. RESULTS: By consolidating trials under a shared standard-of-care control arm, the proposed master protocol design reduces total sample size by as much as 55% when compared with independent trials (with control arm sizes 2.4-2.9 times lower), lowers costs and duration, and enhances enrollment through reduced randomization to controls. Incorporating hybrid controls from prior studies and sharing information among arms with common background standard-of-care further improve efficiency, increasing power (reaching 90% overall) while controlling type I error rates acceptable levels. CONCLUSION: Master protocol designs with hybrid controls and Bayesian information sharing enable the efficient integration of randomization into early-phase oncology trials, enhancing efficiency, cost-effectiveness, and patient-centricity while aligning with FDA OCE initiatives.
- 19 March 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (6) , 162281
25-OH Vitamin D Deficiency Does Not Significantly Predispose Young Children to Multiple Fractures From Minimal Trauma
- 19 March 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 60 (6) , 162281
25-OH Vitamin D Deficiency Does Not Significantly Predispose Young Children to Multiple Fractures From Minimal Trauma
- Open Access
- 1 January 2025
- Published by New England Statistical Society in The New England Journal of Statistics in Data Science
- p. 242-252
Bayesian Information Sharing for Equivalence Testing with an Application to Dose Proportionality Studies
Dose proportionality is an essential aspect of pharmacokinetics (PK). We aim to enhance the efficiency of PK studies by incorporating interim analyses and utilizing data from past trials to increase precision and enable early termination of studies if applicable. In this paper, we extend the multisource exchangeability model (MEM) to the setting with correlated data with interim analyses. Simulation results indicate that the MEM estimators are efficient even with smaller sample sizes, although smaller sample sizes may have higher mean square error (MSE) and bias due to early stopping and more liberal data borrowing from non-exchangeable supplementary sources. Our recommendation is to use a constrained MEM approach when considering small sample sizes, with additional caution needed around the equivalence boundary to better control the inflated type I error rate, bias, and MSE. This research extends the application of MEMs from linear regression models to settings with correlated data using linear mixed effects regression models. It also innovatively applies MEMs to equivalence testing in the context of dose proportionality studies, thereby enhancing their efficiency.
- 1 January 2025
- Published by New England Statistical Society in The New England Journal of Statistics in Data Science
- p. 242-252
Open AccessBayesian Information Sharing for Equivalence Testing with an Application to Dose Proportionality Studies
Dose proportionality is an essential aspect of pharmacokinetics (PK). We aim to enhance the efficiency of PK studies by incorporating interim analyses and utilizing data from past trials to increase precision and enable early termination of studies if applicable. In this paper, we extend the multisource exchangeability model (MEM) to the setting with correlated data with interim analyses. Simulation results indicate that the MEM estimators are efficient even with smaller sample sizes, although smaller sample sizes may have higher mean square error (MSE) and bias due to early stopping and more liberal data borrowing from non-exchangeable supplementary sources. Our recommendation is to use a constrained MEM approach when considering small sample sizes, with additional caution needed around the equivalence boundary to better control the inflated type I error rate, bias, and MSE. This research extends the application of MEMs from linear regression models to settings with correlated data using linear mixed effects regression models. It also innovatively applies MEMs to equivalence testing in the context of dose proportionality studies, thereby enhancing their efficiency.
- Open Access
- 4 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101388
An automated platform trial framework for A/B testing
- 4 November 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 42, 101388
Open AccessAn automated platform trial framework for A/B testing
- 1 July 2024
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 80 (3)
Discussion on “LEAP: the latent exchangeability prior for borrowing information from historical data” by Ethan M. Alt, Xiuya Chang, Xun Jiang, Qing Liu, May Mo, H. Amy Xia, and Joseph G. Ibrahim
This discussion provides commentary on the paper by Ethan M. Alt, Xiuya Chang, Xun Jiang, Qing Liu, May Mo, H. Amy Xia, and Joseph G. Ibrahim entitled “LEAP: the latent exchangeability prior for borrowing information from historical data”. The authors propose a novel method to bridge the incorporation of supplemental information into a study while also identifying potentially exchangeable subgroups to better facilitate information sharing. In this discussion, we highlight the potential relationship with other Bayesian model averaging approaches, such as multisource exchangeability modeling, and provide a brief numeric case study to illustrate how the concepts behind latent exchangeability prior may also improve the performance of existing methods. The results provided by Alt et al. are exciting, and we believe that the method represents a meaningful approach to more efficient information sharing.
- 1 July 2024
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 80 (3)
Discussion on “LEAP: the latent exchangeability prior for borrowing information from historical data” by Ethan M. Alt, Xiuya Chang, Xun Jiang, Qing Liu, May Mo, H. Amy Xia, and Joseph G. Ibrahim
This discussion provides commentary on the paper by Ethan M. Alt, Xiuya Chang, Xun Jiang, Qing Liu, May Mo, H. Amy Xia, and Joseph G. Ibrahim entitled “LEAP: the latent exchangeability prior for borrowing information from historical data”. The authors propose a novel method to bridge the incorporation of supplemental information into a study while also identifying potentially exchangeable subgroups to better facilitate information sharing. In this discussion, we highlight the potential relationship with other Bayesian model averaging approaches, such as multisource exchangeability modeling, and provide a brief numeric case study to illustrate how the concepts behind latent exchangeability prior may also improve the performance of existing methods. The results provided by Alt et al. are exciting, and we believe that the method represents a meaningful approach to more efficient information sharing.
- 24 April 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (11) , 2198-2205
Laryngeal Recalibration Therapy Improves Laryngopharyngeal Symptoms in Patients With Suspected Laryngopharyngeal Reflux Disease
INTRODUCTION: Laryngopharyngeal symptoms such as cough, throat clearing, voice change, paradoxic vocal fold movement, or laryngospasm are hyper-responsive behaviors resulting from local irritation (e.g., refluxate) and heightened sympathetic tone. Laryngeal recalibration therapy (LRT) guided by a speech-language pathologist (SLP) provides mechanical desensitization and cognitive recalibration to suppress hyper-responsive laryngeal patterns. The aim of this study was to assess symptom response to LRT among patients with chronic laryngopharyngeal symptoms undergoing evaluation of gastroesophageal reflux disease (GERD). METHODS: Adults with chronic laryngopharyngeal symptoms referred for evaluation of GERD to a single center were prospectively followed. Inclusion criteria included ≥2 SLP-directed LRT sessions. Data from endoscopy, ambulatory reflux monitoring, and patient-reported outcomes were collected when available. The primary outcome was symptom response. RESULTS: Sixty-five participants completed LRT: mean age 55.4 years (SD 17.2), 46 (71%) female, mean body mass index 25.6 kg/m2 (6.8), and mean of 3.7 (1.9) LRT sessions. Overall, 55 participants (85%) met criteria for symptom response. Specifically, symptom response was similar between those with isolated laryngopharyngeal symptoms (13/15, 87%) and concomitant laryngopharyngeal/esophageal symptoms (42/50, 84%). Among participants who underwent reflux monitoring, symptom response was similar between those with proven, inconclusive for, and no GERD (18/21 [86%], 8/9 [89%], 10/13 [77%]). DISCUSSION: Eighty-five percent of patients with chronic laryngopharyngeal symptoms referred for GERD evaluation who underwent LRT-experienced laryngeal symptom response. Rates of symptom response were maintained across patients with or without proven GERD and patients with or without concomitant esophageal reflux symptoms. SLP-directed LRT is an effective approach to incorporate into multidisciplinary management of chronic laryngopharyngeal symptoms/laryngopharyngeal reflux disease.
- 24 April 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (11) , 2198-2205
Laryngeal Recalibration Therapy Improves Laryngopharyngeal Symptoms in Patients With Suspected Laryngopharyngeal Reflux Disease
INTRODUCTION: Laryngopharyngeal symptoms such as cough, throat clearing, voice change, paradoxic vocal fold movement, or laryngospasm are hyper-responsive behaviors resulting from local irritation (e.g., refluxate) and heightened sympathetic tone. Laryngeal recalibration therapy (LRT) guided by a speech-language pathologist (SLP) provides mechanical desensitization and cognitive recalibration to suppress hyper-responsive laryngeal patterns. The aim of this study was to assess symptom response to LRT among patients with chronic laryngopharyngeal symptoms undergoing evaluation of gastroesophageal reflux disease (GERD). METHODS: Adults with chronic laryngopharyngeal symptoms referred for evaluation of GERD to a single center were prospectively followed. Inclusion criteria included ≥2 SLP-directed LRT sessions. Data from endoscopy, ambulatory reflux monitoring, and patient-reported outcomes were collected when available. The primary outcome was symptom response. RESULTS: Sixty-five participants completed LRT: mean age 55.4 years (SD 17.2), 46 (71%) female, mean body mass index 25.6 kg/m2 (6.8), and mean of 3.7 (1.9) LRT sessions. Overall, 55 participants (85%) met criteria for symptom response. Specifically, symptom response was similar between those with isolated laryngopharyngeal symptoms (13/15, 87%) and concomitant laryngopharyngeal/esophageal symptoms (42/50, 84%). Among participants who underwent reflux monitoring, symptom response was similar between those with proven, inconclusive for, and no GERD (18/21 [86%], 8/9 [89%], 10/13 [77%]). DISCUSSION: Eighty-five percent of patients with chronic laryngopharyngeal symptoms referred for GERD evaluation who underwent LRT-experienced laryngeal symptom response. Rates of symptom response were maintained across patients with or without proven GERD and patients with or without concomitant esophageal reflux symptoms. SLP-directed LRT is an effective approach to incorporate into multidisciplinary management of chronic laryngopharyngeal symptoms/laryngopharyngeal reflux disease.